Telemus Capital’s Aquestive Therapeutics AQST Stock Holding History

Telemus Capital’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-10,000	Closed	-$50K	–	381
2020 Q3	$50K	Buy	+10,000	New	+$65.4K	﹤0.01%	428

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

BCL

Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Telemus Capital's AQST Position: Q4 2020 in Review

Telemus Capital sold out of Aquestive Therapeutics (AQST) in Q4 2020, closing a stake of 10,000 shares — an estimated $50K sold.

Telemus Capital first reported a position in AQST in Q3 2020 and held it in 1 quarter. The position peaked at $50K in Q3 2020. 65 funds tracked by Wall St. Rank hold AQST as of Q4 2020.

Telemus Capital reported no remaining Aquestive Therapeutics position as of Q4 2020 after selling out during the quarter.
Telemus Capital sold 10,000 Aquestive Therapeutics shares in Q4 2020, an estimated $50K.
Telemus Capital first reported a position in Aquestive Therapeutics in Q3 2020 and held it in 1 quarter.
Telemus Capital's Aquestive Therapeutics position peaked at $50K in Q3 2020.
65 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2020.

Based on Telemus Capital's 13F filing for Q4 2020, filed 28 Jan 2021.